Aubagio® delays onset of clinically definite MS, study
Aubagio® delays onset of clinically definite MS, study
Genzyme, a Sanofi company, announced today positive top-line results from the TOPIC trial for Aubagio (teriflunomide). The trial was designed to assess whether early initiation of Aubagio (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS)..... Read More - http://www.ms-uk.org/index.cfm/aubagio
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1330 Views
-
Last post by NHE
-
- 0 Replies
- 710 Views
-
Last post by NHE
-
- 0 Replies
- 961 Views
-
Last post by NHE
-
- 0 Replies
- 2053 Views
-
Last post by frodo
-
- 0 Replies
- 1163 Views
-
Last post by frodo
-
- 1 Replies
- 918 Views
-
Last post by jimmylegs
-
- 0 Replies
- 1897 Views
-
Last post by vesta
-
- 0 Replies
- 1636 Views
-
Last post by DIM
-
- 0 Replies
- 1855 Views
-
Last post by DIM